HRP20150759T1 - Ekspresija gena i bolovi - Google Patents

Ekspresija gena i bolovi Download PDF

Info

Publication number
HRP20150759T1
HRP20150759T1 HRP20150759TT HRP20150759T HRP20150759T1 HR P20150759 T1 HRP20150759 T1 HR P20150759T1 HR P20150759T T HRP20150759T T HR P20150759TT HR P20150759 T HRP20150759 T HR P20150759T HR P20150759 T1 HRP20150759 T1 HR P20150759T1
Authority
HR
Croatia
Prior art keywords
transcription factor
pharmaceutical composition
oligonucleotide
oligonucleotide trap
pain
Prior art date
Application number
HRP20150759TT
Other languages
English (en)
Croatian (hr)
Inventor
Julien Mamet
Original Assignee
Adynxx, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adynxx, Inc. filed Critical Adynxx, Inc.
Publication of HRP20150759T1 publication Critical patent/HRP20150759T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/13—Decoys
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
HRP20150759TT 2007-05-11 2008-05-12 Ekspresija gena i bolovi HRP20150759T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US91758307P 2007-05-11 2007-05-11
PCT/US2008/063471 WO2008141308A2 (en) 2007-05-11 2008-05-12 Gene expression and pain
EP08755344.2A EP2158316B1 (en) 2007-05-11 2008-05-12 Gene expression and pain

Publications (1)

Publication Number Publication Date
HRP20150759T1 true HRP20150759T1 (hr) 2015-08-14

Family

ID=40002879

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20150759TT HRP20150759T1 (hr) 2007-05-11 2008-05-12 Ekspresija gena i bolovi

Country Status (13)

Country Link
US (5) US7943591B2 (https=)
EP (3) EP3199635B1 (https=)
JP (5) JP5646320B2 (https=)
AU (1) AU2008251320B2 (https=)
CA (1) CA2723672C (https=)
DK (1) DK2158316T3 (https=)
ES (2) ES2619314T3 (https=)
HR (1) HRP20150759T1 (https=)
HU (1) HUE025701T2 (https=)
PL (1) PL2158316T3 (https=)
PT (1) PT2158316E (https=)
SI (1) SI2158316T1 (https=)
WO (1) WO2008141308A2 (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2723672C (en) 2007-05-11 2019-09-03 Adynxx, Inc. Gene expression and pain
RU2572826C2 (ru) 2008-12-02 2016-01-20 Чиралджен, Лтд. Способ синтеза модифицированных по атому фосфора нуклеиновых кислот
CA2767253A1 (en) 2009-07-06 2011-01-13 Ontorii, Inc. Novel nucleic acid prodrugs and methods of use thereof
US8609617B2 (en) 2009-09-04 2013-12-17 University Of Miami KLF family members regulate intrinsic axon regeneration ability
JP5868324B2 (ja) 2010-09-24 2016-02-24 株式会社Wave Life Sciences Japan 不斉補助基
AU2012284265B2 (en) 2011-07-19 2017-08-17 Wave Life Sciences Ltd. Methods for the synthesis of functionalized nucleic acids
US20130071444A1 (en) 2011-09-16 2013-03-21 The Charlotte-Mecklenburg Hospital Authority D/B/A Carolinas Healthcare System Amphiphilic Cationic Polymers and Methods of Use Thereof
US9139829B2 (en) * 2012-02-28 2015-09-22 Medical Diagnostic Laboratories, Llc SiRNA targeting ETS1 and ELK1 and method of using same in the inhibition of CIP2A gene in cancer treatment
EP3511022A1 (en) * 2012-05-10 2019-07-17 Adynxx, Inc. Formulations for the delivery of active ingredients
CN104684923B (zh) 2012-07-13 2018-09-28 株式会社新日本科学 手性核酸佐剂
SG11201500239VA (en) 2012-07-13 2015-03-30 Wave Life Sciences Japan Asymmetric auxiliary group
JP6453212B2 (ja) 2012-07-13 2019-01-16 ウェイブ ライフ サイエンシズ リミテッドＷａｖｅ Ｌｉｆｅ Ｓｃｉｅｎｃｅｓ Ｌｔｄ． キラル制御
GB201310853D0 (en) * 2013-06-18 2013-07-31 Ucb Pharma Sa Method
JPWO2015108046A1 (ja) 2014-01-15 2017-03-23 株式会社新日本科学 抗アレルギー作用を有するキラル核酸アジュバンド及び抗アレルギー剤
WO2015108048A1 (ja) 2014-01-15 2015-07-23 株式会社新日本科学 抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤
WO2015108047A1 (ja) 2014-01-15 2015-07-23 株式会社新日本科学 免疫誘導活性を有するキラル核酸アジュバンド及び免疫誘導活性剤
ES2917473T3 (es) 2014-01-16 2022-07-08 Wave Life Sciences Ltd Diseño quiral
JP6705807B2 (ja) * 2014-08-15 2020-06-03 エーダイニクス インコーポレイテッド 疼痛を治療するためのオリゴヌクレオチドデコイ
JP6993230B2 (ja) * 2015-09-09 2022-01-13 アンジェス株式会社 キメラデコイ
US20200017853A1 (en) * 2016-02-29 2020-01-16 Adynxx, Inc. Compositions and methods for pain amelioration via modification of gene expression
US20260078376A1 (en) * 2022-08-26 2026-03-19 Core Biotherapeutics, Inc. Oligonucleotides for the treatment of breast cancer

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6410516B1 (en) 1986-01-09 2002-06-25 President & Fellows Of Harvard College Nuclear factors associated with transcriptional regulation
US5206152A (en) 1988-04-08 1993-04-27 Arch Development Corporation Cloning and expression of early growth regulatory protein genes
DE3815221C2 (de) 1988-05-04 1995-06-29 Gradinger F Hermes Pharma Verwendung einer Retinol- und/oder Retinsäureester enthaltenden pharmazeutischen Zubereitung zur Inhalation zur Einwirkung auf die Schleimhäute des Tracheo-Bronchialtraktes einschließlich der Lungenalveolen
US5272056A (en) 1991-01-03 1993-12-21 The Research Foundation Of State University Of New York Modification of DNA and oligonucleotides using metal complexes of polyaza ligands
US5683985A (en) 1991-04-18 1997-11-04 The Salk Institute For Biological Studies Oligonucleotide decoys and methods relating thereto
FR2675803B1 (fr) 1991-04-25 1996-09-06 Genset Sa Oligonucleotides fermes, antisens et sens et leurs applications.
WO1995004064A1 (en) 1993-07-29 1995-02-09 The Regents Of The University Of California Polynucleotide decoys that ihnibit mhc-ii expression and uses thereof
EP1350514A3 (en) 1993-10-29 2004-07-07 The Brigham And Women's Hospital, Inc. Therapeutic use of cis-element decoys in vivo
WO1996016074A1 (en) 1994-11-17 1996-05-30 Taiho Pharmaceutical Co., Ltd. Double-stranded oligonucleotide and carcinostatic agent containing the same as active ingredient
AU5369396A (en) 1995-03-23 1996-10-08 Research Foundation Of The State University Of New York, The Rest protein and dna
JP4173539B2 (ja) 1995-05-11 2008-10-29 ラボラトアール・セローノ・ソシエテ・アノニム Ｉｌ−６活性阻害剤
EP0824918B1 (en) 1995-05-12 2007-03-28 AnGes MG, Inc. REMEDY AND PREVENTIVE FOR DISEASES CAUSED BY NF-kappaB
GB9515356D0 (en) 1995-07-26 1995-09-20 Medical Res Council Improvements in or relating to delivery of nucleic acid
US6265389B1 (en) 1995-08-31 2001-07-24 Alkermes Controlled Therapeutics, Inc. Microencapsulation and sustained release of oligonucleotides
WO1997044064A2 (en) 1996-05-20 1997-11-27 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Oligonucleotides which specifically bind retroviral nucleocapsid proteins
US6022863A (en) 1996-05-21 2000-02-08 Yale University Regulation of gene expression
JP4215219B2 (ja) 1997-07-04 2009-01-28 アンジェスＭｇ株式会社 脳保護剤
JP3667047B2 (ja) 1997-09-12 2005-07-06 キヤノン株式会社 人工核酸およびその製造方法、デオキシリボフラノース化合物、リボフラノース化合物およびこれらの製造方法
WO1999018792A1 (en) 1997-10-10 1999-04-22 Johns Hopkins University Gene delivery compositions and methods
US6060310A (en) 1997-11-24 2000-05-09 The United States Of America As Represented By The Department Of Health And Human Services Transcription factor decoy and tumor growth inhibitor
AU1656299A (en) 1997-12-16 1999-07-05 University Of Saskatchewan Conductive metal-containing nucleic acids
DE69910202T2 (de) 1998-06-02 2004-06-17 Glaxo Group Ltd., Greenford EGR-1 zur Herstellung eines Medikamentes zur Behandlung von Wunden
US6818626B1 (en) 1998-07-17 2004-11-16 Mirus Corporation Chelating systems for use in the delivery of compounds to cells
US6867289B1 (en) 1998-10-26 2005-03-15 Board Of Regents, The University Of Texas Systems Thio-modified aptamer synthetic methods and compositions
US6008048A (en) 1998-12-04 1999-12-28 Isis Pharmaceuticals Inc. Antisense inhibition of EGR-1 expression
US7160869B2 (en) 1998-12-16 2007-01-09 University Of Saskatchewan Biologically active metal-containing nucleic acids
AU761136B2 (en) 1998-12-23 2003-05-29 Genentech Inc. Transfectacons comprising calcium phosphate and a nucleic acid
US6395029B1 (en) 1999-01-19 2002-05-28 The Children's Hospital Of Philadelphia Sustained delivery of polyionic bioactive agents
US6333408B1 (en) 1999-03-08 2001-12-25 Kureha Chemical Industry Co., Ltd. Oligonucleotides inhibitors of PAI-1 MRNA
FR2790955B1 (fr) 1999-03-19 2003-01-17 Assist Publ Hopitaux De Paris Utilisation d'oligonucleotides stabilises comme principe actif antitumoral
CA2300328A1 (en) 1999-09-14 2001-03-14 Cardiogene Gentherap. Systeme Ag Modulating transcription of genes in vascular cells
US6927027B2 (en) 1999-12-21 2005-08-09 Ingeneus Corporation Nucleic acid multiplex formation
US6969704B1 (en) 2000-08-25 2005-11-29 The Trustees Of Columbia University In The City Of New York Methods for suppressing early growth response—1protein (Egr-1) to reduce vascular injury in a subject
DE10049549A1 (de) 2000-10-06 2002-05-02 Markus Hecker Modulation der Transkription pro-inflammatorischer Genprodukte
WO2002030355A2 (en) 2000-10-11 2002-04-18 Laura Kragie Composition and method of alleviating adverse side effects and/or enhancing efficacy of agents that inhibit aromatase
EP1344536A4 (en) 2000-11-24 2005-01-19 Chugai Pharmaceutical Co Ltd METHOD FOR REGULATING THE EFFECT OF THE EXPRESSION PRODUCT OF A GENE TRANSFERRED IN A LIVING BODY
WO2002066071A2 (en) 2001-01-03 2002-08-29 Thomas Jefferson University Treatment of tissue fibrosis by blocking the sp1 transcription factor
AU2002241952A1 (en) 2001-01-22 2002-07-30 Genta Incorporated Cell-proliferative disorder treatments using cre decoy oligomers, bcl-2 antisense and hybrid oligomers
TWI308492B (https=) 2001-02-20 2009-04-11 Anges Mg Inc
AU2002254132A1 (en) 2001-03-06 2002-09-19 Sierra Sciences, Inc. Methods and compositions for modulating telomerase reverse transcriptase (tert) expression
US20030166555A1 (en) 2001-04-02 2003-09-04 Alberini Cristina M. Methods and compositions for regulating memory consolidation
EP1298141A1 (en) 2001-09-27 2003-04-02 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Interleukin-4 (IL-4) promoter sequences specifically interacting with IRF-1 and IRF-2
DE10148828B4 (de) 2001-10-04 2005-05-19 Avontec Gmbh Modulation der Expression STAT-1-abhängiger Gene
US6663880B1 (en) 2001-11-30 2003-12-16 Advanced Cardiovascular Systems, Inc. Permeabilizing reagents to increase drug delivery and a method of local delivery
EP1496835A4 (en) 2002-02-01 2006-10-18 Omeros Corp COMPOSITIONS AND METHODS FOR THE SYSTEMIC SUPPRESSION OF CARTON DECOMPOSITION
CN1240439C (zh) 2002-03-28 2006-02-08 南京凯基生物科技发展有限公司 肿瘤基因开关药物
AU2002255285B2 (en) 2002-04-26 2008-03-06 Anges Mg, Inc. Circular dumbbell decoy oligodeoxynucleotides (CDODN) containing DNA bindings sites of transcription
DE10242319A1 (de) 2002-09-12 2004-03-25 Avontec Gmbh Funkionelle Korrektur der-786C/T-Varianz des humanen eNOS-Gens
DE10257421A1 (de) 2002-12-09 2004-07-08 Grünenthal GmbH Regulatorische Elemente im 5'-Bereich des VR1-Gens
PT1585548T (pt) 2002-12-09 2018-10-17 Abraxis Bioscience Llc Composições e métodos de administração de agentes farmacológicos
EP1644532A4 (en) 2003-06-30 2007-11-28 Massachusetts Inst Technology EGR GENES AS OBJECTIVES FOR DIAGNOSIS AND TREATMENT OF SCHIZOPHRENIA
US20080233644A1 (en) * 2003-09-12 2008-09-25 Helen Fillmore Chimeric Transcription Factor Decoy Oligonucleotides
JP2005336081A (ja) * 2004-05-26 2005-12-08 Anges Mg Inc Ｎｒ２ｂ−ｎｍｄａ受容体の再発現抑制剤
US7482158B2 (en) 2004-07-01 2009-01-27 Mathison Brian H Composite polynucleic acid therapeutics
US20060293264A1 (en) 2004-07-22 2006-12-28 Grandis Jennifer R STAT3 decoy oligonucleotides and uses therefor
AU2005286640A1 (en) 2004-09-21 2006-03-30 Anesiva, Inc. Delivery of polynucleotides
AU2005288522B2 (en) 2004-09-28 2012-06-28 Quark Pharmaceuticals, Inc. Oligoribonucleotides and methods of use thereof for treatment of alopecia, acute renal failure and other diseases
CA2583576A1 (en) 2004-10-22 2006-04-27 Anges Mg, Inc. Chimera (double) decoy
US7585848B2 (en) * 2005-01-11 2009-09-08 Rush University Medical Center Methods and compositions for treating, inhibiting and reversing disorders of the intervertebral disc
US8268572B2 (en) * 2005-03-04 2012-09-18 Dana-Farber Cancer Institute, Inc. Methods to identify inhibitors of Runx1-mediated expression of nociceptive receptors and ion channels
US7680060B2 (en) * 2005-03-08 2010-03-16 Cisco Technology, Inc. Transferring state information in a network
ATE524546T1 (de) 2005-03-25 2011-09-15 Medtronic Inc Verwendung von anti-tnf oder anti-il1-rnai zur unterdrückung der wirkung entzündungsfördernder cytokine zur lokalen schmerzbehandlung
ES2845146T3 (es) 2006-10-09 2021-07-26 Neurofluidics Inc Sistema de purificación de líquido cefalorraquídeo
CN101686939B (zh) 2007-04-17 2013-03-27 巴克斯特国际公司 用于肺部投送的核酸微粒
CA2723672C (en) * 2007-05-11 2019-09-03 Adynxx, Inc. Gene expression and pain
BR112013003875B1 (pt) 2010-08-20 2021-10-05 Replicor Inc Composições farmacêuticas compreendendo complexo de quelato de oligonucleotídeo, formulação de oligonucleotídeo, e usos
US20140275211A1 (en) 2011-06-21 2014-09-18 Alnylam Pharmaceuticals, Inc. Assays and methods for determining activity of a therapeutic agent in a subject
MY166036A (en) 2011-07-20 2018-05-21 Hospira Inc Methods of treating pain
EP3511022A1 (en) 2012-05-10 2019-07-17 Adynxx, Inc. Formulations for the delivery of active ingredients
MY168778A (en) 2012-05-18 2018-12-04 Replicor Inc Oligonucleotide chelate complex-polypeptide compositions and methods
JP6705807B2 (ja) 2014-08-15 2020-06-03 エーダイニクス インコーポレイテッド 疼痛を治療するためのオリゴヌクレオチドデコイ
US20200017853A1 (en) 2016-02-29 2020-01-16 Adynxx, Inc. Compositions and methods for pain amelioration via modification of gene expression

Also Published As

Publication number Publication date
CA2723672C (en) 2019-09-03
US8093225B2 (en) 2012-01-10
HUE025701T2 (en) 2016-04-28
US8741864B2 (en) 2014-06-03
AU2008251320A1 (en) 2008-11-20
US20120232131A1 (en) 2012-09-13
EP2818550B1 (en) 2016-12-28
WO2008141308A2 (en) 2008-11-20
US20110166212A1 (en) 2011-07-07
US7943591B2 (en) 2011-05-17
JP2016014070A (ja) 2016-01-28
SI2158316T1 (sl) 2015-08-31
US10041069B2 (en) 2018-08-07
PL2158316T3 (pl) 2015-10-30
JP5890869B2 (ja) 2016-03-22
EP3199635B1 (en) 2019-02-06
CA2723672A1 (en) 2008-11-20
ES2619314T3 (es) 2017-06-26
EP2158316A2 (en) 2010-03-03
US20140343132A1 (en) 2014-11-20
JP2010526541A (ja) 2010-08-05
US20080300209A1 (en) 2008-12-04
US9290762B2 (en) 2016-03-22
US20160222382A1 (en) 2016-08-04
PT2158316E (pt) 2015-07-20
JP2014198053A (ja) 2014-10-23
AU2008251320B2 (en) 2013-12-19
WO2008141308A3 (en) 2009-03-05
JP2016117775A (ja) 2016-06-30
JP6082796B2 (ja) 2017-02-15
JP2017148074A (ja) 2017-08-31
JP5646320B2 (ja) 2014-12-24
EP2818550A1 (en) 2014-12-31
EP2158316B1 (en) 2015-04-15
ES2542511T3 (es) 2015-08-06
JP6306075B2 (ja) 2018-04-04
DK2158316T3 (en) 2015-07-20
EP3199635A1 (en) 2017-08-02
HK1205530A1 (en) 2015-12-18
EP2158316A4 (en) 2011-11-09

Similar Documents

Publication Publication Date Title
HRP20150759T1 (hr) Ekspresija gena i bolovi
JP2010526541A5 (https=)
AR081993A1 (es) TRATAMIENTO DE ENFERMEDADES RELACIONADAS CON LA SUBUNIDAD a REGULADA POR VOLTAJE DEL CANAL DE SODIO (SCNA) POR INHIBICION DEL TRANSCRIPTO ANTISENTIDO NATURAL DE SCNA
BR112023021978A2 (pt) Compostos de carbóxi-benzimidazol moduladores de glp-1r
BR112021023632A2 (pt) Métodos e composições para gerar óxido nítrico e usos do mesmo para entregar óxido nítrico através do trato respiratório
BRPI0510475A (pt) adenovìrus quimérico para o uso no tratamento de cáncer
WO2005116250A3 (en) Viral and viral associated mirnas and uses thereof
ATE514777T1 (de) Verbindungen und verfahren zur modulation von genexpression
WO2005000201A3 (en) Modulation of apolipoprotein (a) expression
BRPI0513081A (pt) método para modular a expressão gênica pela alteração do conteúdo de cpg, sistema de expressão, medicamento que o compreende e respectivos usos
BR112012007294A2 (pt) moléculas de ligação a dll4
WO2004048526A3 (en) MODULATION OF HIF1α AND HIF2α EXPRESSION
JP2004537260A5 (https=)
NZ598063A (en) Gram-positive bacteria specific binding compounds
BR112023026862A2 (pt) Compostos de oligonucleotídeos anti-flt1 otimizados para tratamento de pré-eclâmpsia e outros distúrbios angiogênicos
SG157299A1 (en) Diagnosis and treatment of kawasaki disease
EP1250157A4 (en) ANTISENS MODULATION OF THE EXPRESSION OF THE INDUCIBLE NITROGEN MONOXIDE SYNTHASE
EP4650364A3 (en) Materials and methods for treatment of pain related disorders
WO2008108830A8 (en) Immunogenic and therapeutic compositions for streptococcus pyogenes
JP2017529834A5 (https=)
CY1121945T1 (el) Προφυλακτικος και θεραπευτικος παραγοντας της ινωσης
WO2004055162A3 (en) Modulation of endothelial lipase expression
WO2003014306A3 (en) Antisense modulation of cholesteryl ester transfer protein expression
WO2012097057A3 (en) Methods, compositions and kits for modulating trans-differentiation of muscle satellite cells
WO2009097672A3 (en) Pharmaceutical composition, dressing and method for treating skin lesion, intermediate composition and process for preparing said dressing, and use of cerium salt associated with a collagen matrix